# A rare case report: multiple intrahepatic masses in a pediatric patient with citrin deficiency

**Authors:** Hui Lin, Hong Jiang, Qiang Chen, Xiang Pan, Mei Deng, Xiang-Ran Cai, Yuan-Zhi Lu, Yuan-Zong Song, Jun-Cheng Liu

PMC · DOI: 10.1007/s12672-024-01059-0 · 2024-05-31

## TL;DR

A child with citrin deficiency developed hepatoblastoma, a rare liver cancer, suggesting a possible link between the two conditions.

## Contribution

This is the first reported case of hepatoblastoma in a pediatric patient with citrin deficiency.

## Key findings

- The patient had multiple intrahepatic masses and elevated AFP levels, leading to a hepatoblastoma diagnosis.
- Hepatoblastoma recurred rapidly after initial treatment, resulting in the patient's death.
- This case raises the possibility of an association between citrin deficiency and hepatoblastoma in children.

## Abstract

Deficiency of citrin, the liver-type aspartate-glutamate carrier, arises from biallelic mutations of the gene SLC25A13. Although citrin deficiency (CD) is associated with higher risk of hepatocellular carcinoma (HCC) in adult patients, this association remains inconclusive in pediatric cases. The patient in this paper had been diagnosed to have CD by SLC25A13 analysis at the age 10 months, and then in response to dietary therapy, her prolonged jaundice and marked hepatosplenomegaly resolved gradually. However, she was referred to the hospital once again due to recurrent abdominal distention for 2 weeks at her age 4 years and 9 months, when prominently enlarged liver and spleen were palpated, along with a strikingly elevated serum alpha-fetoprotein (AFP) level of 27605 ng/mL as well as a large mass in the right liver lobe and a suspected tumor thrombus within the portal vein on enhanced computed tomography. After 4 rounds of adjuvant chemotherapy, right hepatic lobectomy and portal venous embolectomy were performed at her age 5 years and 3 months, and metastatic hepatoblastoma was confirmed by histopathological analysis. Afterwards, the patient underwent 5 additional cycles of chemotherapy and her condition remained stable for 7 months after surgery. Unfortunately, hepatoblastoma recurred in the left lobe at the age 5 years and 10 months, which progressed rapidly into liver failure, and led to death at the age 6 years and 1 month. As far as we know, this is the the first case of hepatoblastoma in a patient with CD, raising the possibility of an association between these two conditions.

## Linked entities

- **Genes:** SLC25A13 (solute carrier family 25 member 13) [NCBI Gene 10165]
- **Proteins:** SLC25A13 (solute carrier family 25 member 13)
- **Diseases:** citrin deficiency (MONDO:0011326), hepatoblastoma (MONDO:0018666), hepatocellular carcinoma (MONDO:0007256), liver failure (MONDO:0100192)

## Full-text entities

- **Genes:** SLC25A13 (solute carrier family 25 member 13) [NCBI Gene 10165] {aka ARALAR2, CITRIN, CTLN2, NICCD}, AFP (alpha fetoprotein) [NCBI Gene 174] {aka AFPD, FETA, HPAFP}
- **Diseases:** death (MESH:D003643), HCC (MESH:D006528), abdominal distention (MESH:D000007), hepatosplenomegaly (MESH:C535727), CD (MESH:C538053), aspartate-glutamate (MESH:C536171), tumor thrombus (MESH:D013927), liver failure (MESH:D017093), hepatoblastoma (MESH:D018197), intrahepatic masses (MESH:C536030), jaundice (MESH:D007565)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11143117/full.md

---
Source: https://tomesphere.com/paper/PMC11143117